Insilico expands Tenacia CNS partnership in $94.75M AI deal

Insilico Medicine said on March 26, 2026 that it is expanding its central nervous system collaboration with Tenacia Biotechnology in a deal worth up to $94.75 million. The companies said the expanded agreement adds work on another innovative molecule candidate for neurological diseases, with the goal of advancing it to the preclinical candidate stage. The move builds on an initial research collaboration launched in March 2025, which paired Insilico’s generative AI drug discovery platform with Tenacia’s CNS biology and development expertise. It also extends a broader run of business development activity for Insilico, which recently announced CNS and autoimmune collaborations with CMS and a separate multibillion-dollar AI drug discovery deal with Eli Lilly. (prnewswire.com)

Why it matters: For veterinary professionals, this isn’t a companion animal pipeline story, but it is another sign that AI-enabled drug discovery platforms are continuing to attract real partnership dollars in hard-to-treat disease areas like CNS disorders. That matters because the same discovery infrastructure Insilico says it uses in human therapeutics is also being positioned for applications in veterinary medicine, suggesting the tools and deal structures shaping human biopharma could increasingly influence how future animal health programs are identified, designed, and advanced. (prnewswire.com)

What to watch: Watch for whether the expanded Tenacia program reaches preclinical candidate nomination on the 12- to 18-month timetable Insilico has cited for many of its AI-enabled discovery efforts. (prnewswire.com)